<DOC>
	<DOCNO>NCT01526564</DOCNO>
	<brief_summary>Chemotherapy-induced peripheral neuropathy ( CIPN ) common clinical dose-limiting adverse drug reaction , primary manifestation different degree neuromotor , sensorineural autonomic nervous dysfunction .</brief_summary>
	<brief_title>Clinical Study Acetyl-L-Carnitine</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled parallel clinical trial observe efficacy safety Acetyl-L-Carnitine Hydrochloride enteric-coated tablet treatment peripheral sensory neuropathy anti-cancer chemotherapeutics induce .</detailed_description>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>Patients sign Informed Consent Form Male Female Age 1875 year old Patients treated Taxoids , Satraplatin Vincristine ; The peripheral sensory neuropathy grade chemotherapy &gt; /=grade 3 grade 2 last one month The course neuropathy &lt; /=6 month No need continue chemotherapy accord condition refuse chemotherapy At least one neuroelectrophysiological examine result abnormal Physical Condition Score ( KPS ) &gt; /=60 Anticipated lifetime &gt; /=60 . Patients whose peripheral sensory neuropathy induce medicine except Taxoids , Satraplatin vincristine anticancer chemotherapeutics Diabetics Peripheral sensory neuropathy induce Vitamin deficiency , infection , trauma , toxicosis , compression , ischemia Peripheral sensory neurologic dysfunction induce lesion central nervous system ; hereditary neuropathy Patients treat medicine peripheral sensory neuropathy 30 day Patients treat clinical trial medicine participate trial 30 day Patients active infection Any clinical problem control Women pregnancy lactation , Subjects compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Weeks</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chemotherapy-induced peripheral neuropathy ( CIPN )</keyword>
</DOC>